Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference Read more about Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 Read more about Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Read more about Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference Read more about Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Read more about Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis Read more about Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference Read more about Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference Read more about Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 Read more about Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis Read more about Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
